Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that PharmaVoice, one of the leading industry publications in the life sciences industry, has selected Dr. Niranjan Sardesai as one of its 100 most inspiring leaders of 2015. Dr. Sardesai is the Chief Operating Officer of Inovio, a leading developer of innovative cancer and infectious disease treatment and preventive therapies. Those chosen for this elite group are selected for their positive contributions as leaders who think differently, address the big challenges facing the industry, and lead teams through inspiration. These leaders will gather in New York City on September 17, 2015 for a celebration of their selection.

Dr. Sardesai has broad operating and consulting experience in biotechnology and pharmaceuticals. He is responsible for leading the company’s product development programs in infectious disease and cancer immunotherapies and delivery systems. He has secured over $130 million in non-dilutive funding through government and NGO grants and contracts and was Inovio’s lead executive in completing Inovio’s two big pharma licensing deals with Roche and MedImmune in the last two years.

Under his leadership the company has advanced immunotherapy programs for cervical dysplasia, HIV, and cancers that are now in clinical studies. He currently serves as the principal investigator on an NIAID-funded HVDDT contract for the development of HIV vaccines and DARPA-funded Ebola vaccine and therapeutics programs.

Prior to Inovio, Dr. Sardesai oversaw R&D and expansion of the oncology portfolio at Fujirebio Diagnostics, Inc.Products developed under his leadership include new-to-the-world tests for mesothelioma (MESOMARK), bladder cancer and a multi-marker test for ovarian cancer. He has authored over 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents.

Dr. Sardesai said, “I am honored to be named as one of the 100 most inspiring people in the life science industry. This prestigious recognition by PharmaVoice has been possible because of the dedication of the Inovio people in our R&D, business development and commercial functions.”

Dr. J. Joseph Kim, President and CEO, said, “According to PharmaVoice, their 100 Award is a means to celebrate the men and women who provide inspiration to their peers, colleagues, and companies through their innovative and motivation approaches to addressing the industry’s myriad challenges. We knew that about Niranjan already, and all of us at Inovio are proud that he has been counted among these honored few.”

Established more than 10 years ago by PharmaVoice magazine, the PharmaVoice 100 is an annual list of individuals recognized for their positive contributions to the life science industry. Selected from thousands of nominations, the distinguished honorees are selected based on substantive accounts describing how they have inspired or motivated their colleagues, peers, and even competitors, have affected positive changes in their own organizations, as well as give back to their communities and other philanthropic causes. (Original Source)

Shares of Inovio Pharmaceuticals closed yesterday at $7.35. INO has a 1-year high of $13.04 and a 1-year low of $6.19. The stock’s 50-day moving average is $7.24 and its 200-day moving average is $8.15.

On the ratings front, Inovio Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on September 9, Maxim Group analyst Jason Kolbert reiterated a Buy rating on INO, with a price target of $23, which implies an upside of 212.9% from current levels. Separately, on August 10, Brean Murray Carret’s Jonathan Aschoff reiterated a Buy rating on the stock and has a price target of $20.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Jonathan Aschoff have a total average return of -9.0% and 7.0% respectively. Kolbert has a success rate of 34.6% and is ranked #3732 out of 3757 analysts, while Aschoff has a success rate of 44.8% and is ranked #432.

The street is mostly Bullish on INO stock. Out of 4 analysts who cover the stock, 4 suggest a Buy rating . The 12-month average price target assigned to the stock is $20.00, which implies an upside of 172.1% from current levels.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.